Literature DB >> 7533113

Hepatitis C viral complexity detected by single-strand conformation polymorphism and response to interferon therapy.

T Moribe1, N Hayashi, Y Kanazawa, E Mita, H Fusamoto, M Negi, T Kaneshige, H Igimi, T Kamada, K Uchida.   

Abstract

BACKGROUND/AIMS: Hepatitis C virus (HCV) genome heterogeneity by sequence analysis in association with interferon (IFN) inefficacy has been reported. This study was performed to establish a convenient method for detecting the HCV quasispecies complexity and to determine the correlation between the complexity and the responsiveness to IFN therapy in patients with chronic hepatitis C.
METHODS: The quasispecies complexity of HCV hypervariable region 1 in patients treated with IFN-alpha was analyzed by polymerase chain reaction-mediated single-strand conformation polymorphism (SSCP).
RESULTS: Seven of 25 patients (28%) with low complexity (SSCP band number of < or = 2) were HCV RNA negative after treatment, whereas in 24 patients with high complexity (SSCP band number of > or = 3), the response to IFN was almost insignificant because only 1 patient (4.5%) remained HCV RNA negative after treatment (P < 0.05). Among type 1b patients, IFN therapy was only effective for patients with low amounts of HCV RNA (< or = 10(7.5) copies/mL serum) and low complexity. In contrast, most type 2a patients tended to respond to the therapy with exceptions being those with high amounts of HCV RNA and high complexity.
CONCLUSIONS: The complexity of the hypervariable region 1 quasispecies may be a factor for predicting IFN inefficacy in patients with chronic hepatitis C.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7533113     DOI: 10.1016/0016-5085(95)90452-2

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  18 in total

1.  Quasispecies as predictive response factors for antiviral treatment in patients with chronic hepatitis C.

Authors:  Javier Salmerón; Paloma Muñoz De Rueda; Angela Ruiz-Extremera; Jorge Casado; Carlos Huertas; Maria Del Carmen Bernal; Luis Rodríguez; Angel Palacios
Journal:  Dig Dis Sci       Date:  2006-05       Impact factor: 3.199

Review 2.  Viral determinants of resistance to treatment in patients with hepatitis C.

Authors:  Anette Wohnsland; Wolf Peter Hofmann; Christoph Sarrazin
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

3.  Long-term evolution of the hypervariable region of hepatitis C virus in a common-source-infected cohort.

Authors:  J McAllister; C Casino; F Davidson; J Power; E Lawlor; P L Yap; P Simmonds; D B Smith
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

Review 4.  [Therapy of hepatitis C].

Authors:  D M Alscher; J C Bode
Journal:  Med Klin (Munich)       Date:  1997-03-15

Review 5.  The quasispecies of hepatitis C virus and the host immune response.

Authors:  P Farci; J Bukh; R H Purcell
Journal:  Springer Semin Immunopathol       Date:  1997

Review 6.  Hepatitis C virus: molecular biology and genetic variability.

Authors:  C Bréchot
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

7.  Genetic heterogeneity of hypervariable region 1 of the hepatitis C virus (HCV) genome and sensitivity of HCV to alpha interferon therapy.

Authors:  K Sandres; M Dubois; C Pasquier; J L Payen; L Alric; M Duffaut; J P Vinel; J P Pascal; J Puel; J Izopet
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

8.  Genetic evolution of structural region of hepatitis C virus in primary infection.

Authors:  Song Chen; Yu-Ming Wang
Journal:  World J Gastroenterol       Date:  2002-08       Impact factor: 5.742

9.  Evolution of interferon-based therapy for chronic hepatitis C.

Authors:  Chun-Hao Chen; Ming-Lung Yu
Journal:  Hepat Res Treat       Date:  2010-10-10

10.  High diversity of hepatitis C viral quasispecies is associated with early virological response in patients undergoing antiviral therapy.

Authors:  Xiaofeng Fan; Qing Mao; Donghui Zhou; Yang Lu; Jianwei Xing; Yanjuan Xu; Stuart C Ray; Adrian M Di Bisceglie
Journal:  Hepatology       Date:  2009-12       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.